JP2013523082A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523082A5
JP2013523082A5 JP2012543839A JP2012543839A JP2013523082A5 JP 2013523082 A5 JP2013523082 A5 JP 2013523082A5 JP 2012543839 A JP2012543839 A JP 2012543839A JP 2012543839 A JP2012543839 A JP 2012543839A JP 2013523082 A5 JP2013523082 A5 JP 2013523082A5
Authority
JP
Japan
Prior art keywords
peptide
isolated
apc
group
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012543839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523082A (ja
JP5816965B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2011/001909 external-priority patent/WO2011122022A1/en
Publication of JP2013523082A publication Critical patent/JP2013523082A/ja
Publication of JP2013523082A5 publication Critical patent/JP2013523082A5/ja
Application granted granted Critical
Publication of JP5816965B2 publication Critical patent/JP5816965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012543839A 2010-04-02 2011-03-30 Ect2ペプチドおよびそれを含むワクチン Active JP5816965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32057710P 2010-04-02 2010-04-02
US61/320,577 2010-04-02
PCT/JP2011/001909 WO2011122022A1 (en) 2010-04-02 2011-03-30 Ect2 peptides and vaccines including the same

Publications (3)

Publication Number Publication Date
JP2013523082A JP2013523082A (ja) 2013-06-17
JP2013523082A5 true JP2013523082A5 (enExample) 2014-05-15
JP5816965B2 JP5816965B2 (ja) 2015-11-18

Family

ID=44711777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543839A Active JP5816965B2 (ja) 2010-04-02 2011-03-30 Ect2ペプチドおよびそれを含むワクチン

Country Status (20)

Country Link
US (1) US8951975B2 (enExample)
EP (1) EP2553096B1 (enExample)
JP (1) JP5816965B2 (enExample)
KR (1) KR101863557B1 (enExample)
CN (1) CN102939379B (enExample)
AR (1) AR081065A1 (enExample)
AU (1) AU2011233401B2 (enExample)
BR (1) BR112012024997B1 (enExample)
CA (1) CA2795318C (enExample)
CO (1) CO6571869A2 (enExample)
DK (1) DK2553096T3 (enExample)
EA (1) EA027940B1 (enExample)
ES (1) ES2655437T3 (enExample)
IL (1) IL222057A (enExample)
MX (1) MX342000B (enExample)
NZ (1) NZ603379A (enExample)
SG (1) SG184165A1 (enExample)
TW (2) TW201627003A (enExample)
WO (1) WO2011122022A1 (enExample)
ZA (1) ZA201207342B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2002030963A1 (en) 2000-10-12 2002-04-18 Exelixis, Inc. Human ect2 and methods of use
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7227007B2 (en) * 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
ES2747357T3 (es) 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
WO2002096943A1 (en) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
JP2005506833A (ja) 2001-06-04 2005-03-10 キュラジェン コーポレイション 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法
WO2002099062A2 (en) 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1882698B (zh) 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
CN101273144B (zh) * 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
EP2004228A1 (en) 2006-02-28 2008-12-24 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-epha4 antibodies
EP2078731A4 (en) 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd ANTI-HB-EGF ANTIBODY AS PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE SUBSTANCE
WO2008047914A1 (fr) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
JP2011528221A (ja) 2008-07-16 2011-11-17 オンコセラピー・サイエンス株式会社 肺癌および食道癌に関する治療標的および予後指標としてのect2癌遺伝子
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Similar Documents

Publication Publication Date Title
JP2012517799A5 (enExample)
JP2016511221A5 (enExample)
JP2013523084A5 (enExample)
JP2012500001A5 (enExample)
JP2011524737A5 (enExample)
JP2010523471A5 (enExample)
JP2013511958A5 (enExample)
RU2012127358A (ru) Олигопептиды imp-3 и содержащие их вакцины
JP2014519311A5 (enExample)
JP2008530975A5 (enExample)
JP2013517764A5 (enExample)
JP2015529219A5 (enExample)
RU2015143164A (ru) Пептиды kntc2 и содержащие их вакцины
JP2012520659A5 (enExample)
RU2013158399A (ru) Пептиды sema5b и содержащие их вакцины
JP2011522777A5 (enExample)
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
RU2014121502A (ru) Пептиды торк и содержащие их вакцины
JP2015524788A5 (enExample)
JP2011529683A5 (enExample)
RU2015113436A (ru) Пептиды ube2t и содержащие их вакцины
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
JP2012526519A5 (enExample)
JP2014533095A5 (enExample)
JP2012527867A5 (enExample)